Form 4 for MGNX MACROGENICS INC
Accepted 2024-02-07 00:00:00 ET · period of report 2024-02-05 · accession 0001125345-24-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-07 | 2024-02-05 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | S - Sale+OE | $16.50 | -76.3K | 0 | -100% | -$1.26M |
| DM | 2024-02-07 | 2024-02-05 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | M - OptEx | $11.11 | +76.3K | 54.4K | New | +$847.4K |
| DM | 2024-02-07 | 2024-02-05 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | M - OptEx | $0.00 | -76.3K | 48.1K | -61% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-05 | S | D | 54,376 | $16.50 | 21,875 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-05 | M | A | 21,875 | $10.15 | 76,251 | D | — | — | |
| 3 | Common | Common Stock | 2024-02-05 | S | D | 21,875 | $16.50 | 0 | D | — | — | |
| 4 | Common | Common Stock | 2024-02-05 | M | A | 54,376 | $11.50 | 54,376 | D | — | — | |
| 5 | Derivative | Employee stock option (right to buy) | 2024-02-05 | M | D | 54,376 | $0.00 | 10,875 | D | $11.50 · — to 2030-02-20 | 54,376 Common Stock | (F2) 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. |
| 6 | Derivative | Employee stock option (right to buy) | 2024-02-05 | M | D | 21,875 | $0.00 | 48,125 | D | $10.15 · — to 2032-02-22 | 21,875 Common Stock | (F2) 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. |